BioSpace News Archive

$23.8M in Rubraca® sales for the second quarter of 2018 compared to $14.6M for Q2 2017

Total revenue, including royalty and other revenue, was $211.6 million

Quadrant Biosciences brain health toolkit recognized for innovation

Reaffirms 2018 Annual Guidance

A new drug-delivery technology which uses red blood cells (RBCs) to shuttle nano-scale drug carriers, called RBC-hitchhiking (RH), has been found in animal models to dramatically increase the concentration of drugs ferried precisely to selected organs, according to a study published in Nature Communications this month by researchers from the Perelman School of Medicine at the University of Pennsylvania.

Wellbridge Healthcare today announced that Gregory D. Drummond has been appointed Chief Executive Officer of the WellBridge Hospital in San Marcos.

Study Begins Evaluation on First Set of Lungs, Will Assess Organs Using Proprietary Grading System

Community Healthcare Trust Incorporated announced that its Board of Directors has increased its common stock cash dividend for the quarter ended June 30, 2018.

Nektar Therapeutics will announce its financial results for the second quarter on Wednesday, August 8, 2018, after the close of U.S.-based financial markets. Howard Robin, president and chief executive officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).

Synthetic Biologics, Inc. announced a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every thirty-five (35) shares of common stock, effective August 10, 2018 (the “Effective Date”).